Follow
solange peters
solange peters
Unknown affiliation
Verified email at chuv.ch
Title
Cited by
Cited by
Year
Comprehensive molecular profiling of lung adenocarcinoma
Cancer Genome Atlas Research Network
Nature 511 (7511), 543, 2014
37842014
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
24652017
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D Planchard, ST Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ...
Annals of Oncology 29, iv192-iv237, 2018
2345*2018
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
S Peters, DR Camidge, AT Shaw, S Gadgeel, JS Ahn, DW Kim, SHI Ou, ...
New England Journal of Medicine 377 (9), 829-838, 2017
22692017
Nivolumab plus ipilimumab in advanced non–small-cell lung cancer
MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ...
New England Journal of Medicine 381 (21), 2020-2031, 2019
21952019
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Haanen, F Carbonnel, C Robert, KM Kerr, S Peters, J Larkin, K Jordan
Annals of oncology 28, iv119-iv142, 2017
21892017
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ...
Annals of Oncology 30 (1), 44-56, 2019
19802019
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
18052020
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste, ...
Annals of oncology 28, iv1-iv21, 2017
16952017
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
F Martins, L Sofiya, GP Sykiotis, F Lamine, M Maillard, M Fraga, ...
Nature reviews Clinical oncology 16 (9), 563-580, 2019
14892019
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Novello, F Barlesi, R Califano, T Cufer, S Ekman, MG Levra, K Kerr, ...
Annals of Oncology 27, v1-v27, 2016
9822016
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Reck, S Popat, N Reinmuth, D De Ruysscher, KM Kerr, S Peters
Annals of oncology 25, iii27-iii39, 2014
7872014
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, ...
The Lancet 397 (10272), 375-386, 2021
7702021
Brain metastases
AS Achrol, RC Rennert, C Anders, R Soffietti, MS Ahluwalia, L Nayak, ...
Nature Reviews Disease Primers 5 (1), 5, 2019
7652019
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
J Mazières, S Peters, B Lepage, AB Cortot, F Barlesi, M Beau-Faller, ...
Journal of clinical oncology 31 (16), 1997-2003, 2013
7292013
Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Haanen, F Carbonnel, C Robert, KM Kerr, S Peters, J Larkin, K Jordan
Annals of Oncology 29, iv264-iv266, 2018
700*2018
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Früh, D De Ruysscher, S Popat, L Crinò, S Peters, E Felip
Annals of oncology 24, vi99-vi105, 2013
6922013
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ...
The Lancet Oncology 21 (7), 914-922, 2020
6412020
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Vansteenkiste, D De Ruysscher, WEE Eberhardt, E Lim, S Senan, ...
Annals of oncology 24, vi89-vi98, 2013
6362013
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Peters, AA Adjei, C Gridelli, M Reck, K Kerr, E Felip
Annals of oncology 23, vii56-vii64, 2012
5732012
The system can't perform the operation now. Try again later.
Articles 1–20